E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
chronic kidney failure |
insufficienza renale cronica |
|
E.1.1.1 | Medical condition in easily understood language |
chronic kidney disease |
malattia renale cronica |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10013346 |
E.1.2 | Term | Disorders of phosphorus metabolism |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Differences in the variation in circulating levels of FGF-23 (T0-T8) in group A and group B |
Differenze nella variazione dei livelli circolanti di FGF-23 (T8-T0) tra il gruppo A e il gruppo B |
|
E.2.2 | Secondary objectives of the trial |
Effects of administration of a chelating phosphorus or counseling on diet and nutritional levels of Vit D, PTH, inflammation, bicarbonatemia, Klotho.Relation between phosphorus content of the diet and levels of FGF-23. |
Effetti della somministrazione di un chelante del fosforo o di un counselling dietetico-nutrizionale sui livelli di Vit D, PTH, infiammazione, bicarbonatemia, Klotho.
Relazione tra contenuto di fosforo della dieta e livelli di FGF-23. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients with CKD stage 2 and 3 with phosphorus> 3.5 mg / dl. |
Pazienti con CKD stadio 2 e 3, con fosforemia > 3.5 mg/dl. |
|
E.4 | Principal exclusion criteria |
Age <18 and> 80 years. Therapy with diphosphonates, calcitriol, corticosteroid therapy, nephrotic syndrome, chronic and acute inflammatory diseases. Psychiatric illness. Serum calcium> 10.5 mg / dl
Pregnancy or breast-feeding. |
Età <18 e >80 anni. Terapia con difosfonati, calcitriolo, terapie con corticosteroidi, sindrome nefrosica, malattie infiammatorie croniche e acute. Malattie psichiatriche. Calcemia >10,5 mg/dl
Gravidanza o allattamento. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Control Mineral Metabolism in the early stages of chronic renal failure |
controllo del metabolismo minerale nelle fasi precoci dell'insufficienza renale cronica |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
effects of administration of a chelating phosphorus dietary-nutritional counseling on FGF 23 levels |
effetti della somministrazione di un chelante del fosforo o di un counselling dietetico nutrizionale sui livelli di FGF 23 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
counselling dietetico-nutrizionale |
diet- nutritional counselling |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |